TearClear Appoints Key Team Members

We’re pleased to share these developments announced by TearClear with you.

In May, Dr. Amir Sjojaei was appointed as TearClear’s Chief Development Officer. His career has focused on the clinical development, registration and commercialization of bio-pharmaceuticals and biologics in multiple therapeutic areas. You can read the press release here, or find an archived PDF here.

In April, Robert J. Dempsey was appointed as Chief Executive Officer. Dempsey, who has more than two decades of experience in the ophthalmic pharmaceutical industry, is expected to accelerate TearClear’s business and commercial strategy, including advancing the robust pipeline and leading the company’s efforts in bringing innovative products to market. You can read the press release here, or find an archived PDF here.

We welcome you to listen to this OIS Podcast (Ophthalmology Innovation Summit), where Dr. Ehsan Sadri speaks with Bob Dempsey about his experience taking Xiidra (Zy-dra) to market for Shire led him to the driver’s seat for one of the most promising new drug-delivery companies.

Shared by Tyler Stowater, board member of TearClear Corp.